SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin informs about press release

28 Sep 2020 Evaluate

Lupin has informed that it has enclosed a Press Release on 28th September 2020 as regards launch by the Company of Fosaprepitant for Injection, 150 mg Single-Dose Vial, having received an approval from the US FDA earlier.

The above information is a part of company’s filings submitted to BSE.

Lupin Share Price

2303.70 -7.20 (-0.31%)
30-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.20
Dr. Reddys Lab 1322.95
Cipla 1309.90
Zydus Lifesciences 891.65
Lupin 2303.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×